NO-sartans: A new class of pharmacodynamic hybrids as cardiovascular drugs

Journal of Medicinal Chemistry

Volumn 47, Issue 23, 2004, Pages 5597-5600

  Breschi, Maria C ^a   Calderone, Vincenzo ^a   Digiacomo, Maria ^a   Martelli, Alma ^a   Martinotti, Enrica ^a   Minutolo, Filippo ^a   Rapposelli, Simona ^a   Balsamo, Aldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROOXYMETHYLBENZOATE; 5 NITROOXYPENTANOATE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CAPTOPRIL; LOSARTAN; LOSARTAN DERIVATIVE; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HYBRID; HYPERTENSION; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; LOSARTAN; RATS; RATS, INBRED SHR; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATOR AGENTS;

EID: 7444244389     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049681p     Document Type: Article

References (39)

1. Mombouli, J. V.; Vanhoutte, P. M. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J. Cardiovasc. Pharmacol. 1992, 20, S74-S82.
2. Linz, W.; Wiemer, G.; Gohlke, P.; Unger, T.; Scholkens, B. A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 1995, 47, 25-49.
3. Auch-Schwelk, W.; Bossaller, C.; Claus, M.; Graf, K.; Gräfe, M.; Fleck, E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc. Res. 1993, 27, 312-317.
4. Danser, A. H. J.; Tom, B.; de Vries, R.; Saxena P. R. L-NAME resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: effect of ACE inhibition. Br. J. Pharmacol. 2000, 131, 195-202.
5. Minshall, R. D.; Erdös, E. G.; Vogel, S. M. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am. J. Cardiol. 1997, 80, 132A-136A.
6. Minshall, R. D.; Nedumgottil, S. J.; Igic, R.; Erdös, E. G.; Rabito, S. F. Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum. Peptides 2000, 21, 1257-1264.
7. Mombouli, J. V.; Ballard, K. D.; Vanhoutte, P. M. Kininase-independent potentiation of endothelium-dependent relaxations to kinins by converting enzyme inhibitor perindoprilat. Acta Pharmacol. Sin. 2002, 23, 203-207.
8. 2 bradykinin receptor by ACE inhibitors. J. Biol. Chem. 2000, 275, 16110-16118.
9. Marin-Castano, M. E.; Schanstra, J. P.; Neau, E.; Praddaude, F.; Pecher, C.; Ader, J. L.; Girolami, J. P.; Bascands, J. L. Induction of functional bradykinin B(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 2002, 105, 627-632.
10. 1 receptor. J. Biol. Chem. 2002, 277, 16847-16852.
11. Israili, Z. H.; Hall, W.D Cough and angioneurotic edema associated with angiotensin-converting enzyme inibitor therapy. A review of literature and pathophysiology. Ann. Intern. Med. 1992, 117, 234-242.
12. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. J. Med. Chem. 1996, 39, 625-656.
13. Okunishi, H.; Oka, Y.; Shiora, N.; Kawamoto, T.; Song, K.; Miyazaki, M. Marked species-difference in the vascular angiotensin II-forming pathways: human versus rodents. Jpn. J. Pharmacol. 1993, 62, 207-210.
14. Tanser, P. H.; Campbell, L. M.; Carranza, J.; Karrash, J.; Toutouzas, P.; Watts, R. Candesartan Cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Am. J. Hypertens. 2000, 13, 214-218.
15. Zorba Paster, R.; Snavely, D. B.; Sweet, A. R.; Drapeq, R. A.; Goldberg, A. I.; Sofieq, B. A.; Sweet, C. S. Use of Losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. Clin. Ther. 1998, 20(5), 978-989.
16. Moncada, S.; Higgs, E. A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329, 2002-2012.
17. Loscalzo, J.; Welch, G.; Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis. 1995, 38, 87, 104.
18. Murrel, W. Nitro-glycerine as remedy for angina pectoris. Lancet 1879, 1, 80-81.
19. Parker, J. O.; Farrel, B.; Lahey, K. A.; Moe, G. Effects of intervals obtained by NicOx SA. Between doses on the development of tolerance to isosorbide dinitrate. N. Engl. J. Med. 1987, 316, 1635-1642.
20. Wallace, J. L.; McKnight, W.; Del Soldato, P.; Cirino, G. Antithrombotic properties of a nitric oxide-releasing gastric sparing aspirin derivative. J. Clin. Invest. 1995, 96, 2711-2718.
21. Minuz, P.; Lechi, C.; Zuliani, V.; Tommasoli, R.; Lechi, A. NO-aspirins: antithrombotic activity of derivatives of acetylsalicylic acid releasing nitric oxide. Cardiovasc. Drug Rev. 1998, 16, 31-47.
22. Gresele, P.; Momi, S.; Mezzasoma, A. M. NCX4016: a novel antithrombotic agent. Dig. Liver Dis. 2003, 35 (2), S20-S26.
23. Bing, R. J.; Yamamoto, T.; Yamamoto, M.; Kakar, R.; Cohen, A. New look at myocardial infarction: toward a better aspirin. Cardiovasc. Res. 1999, 43, 25-31.
24. Rossoni, G.; Berti, M.; de Gennaro Colonna V.; Del Soldato P.; Breti F. Myocardial protection by the nitroderivative of aspirin, NCX 4016: in vitro and in vivo experiments in the rabbit. Ital. Heart J. 2000, 1, 146-155.
25. Rossoni, G.; Manfredi, B.; de Gennaro Colonna, V.; Bernareggi, M.; Berti, F. The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischaemia-reperfusion in the anaesthetized rat. J. Pharmacol. Exp. Ther. 2001, 297, 380-387.
26. Wallace, J. L.; Del Soldato, P. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. 2003, 17, 11-20.
27. Shaffer, J. E.; Lee, F.; Thomson, S.; Han, B. J.; Cooke, J. P.; Lo Scalzo, J. The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. J. Pharmacol. Exp. Ther. 1991, 256, 704-709.
28. Nakae, I.; Takahashi, M.; Kinoshita, T.; Matsumoto, T.; Kinoshita, M. The effects of S-Nitrosocaptopril on canine coronary circulation. J. Pharmacol. Exp. Ther. 1995, 274, 40-46.
29. Korzycka, L.; Owczarek, J.; Czarnecka, E. A study on organic nitrates, Part VI. Synthesis and pharmacological activity of 1-isopropylamino-3-(1- naphthyloxy)-2-propyl nitrate. Acta Pol. Pharm. 2002, 59 (5), 365-369.
30. Villarroya, M.; Herrero, C. J.; Ruiz-Nuno, A.; de Pascual, R.; del Valle, M.; Michelena, P.; Grau, M.; Carrasco, E.; Lopez, M. G.; Garcia, A. G. PF9404C, a new slow NO donor with beta receptor blocking properties. Br. J. Pharmacol. 1999, 128 (8), 1713-22.
31. Boschi, D.; Di Stilo, A.; Cena, C.; Lolli, M.; Fruttero, R.; Gasco, A. Studies on agents with mixed NO-dependent vasodilating and beta-blocking activities. Pharmacol. Res. 1997, 14 (12), 1750-8.
32. Di Stilo, A.; Visentin, S.; Cena, C.; Gasco, A. M.; Ermondi, G.; Gasco, A. New 1,4-Dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities. J. Med. Chem. 1998, 41, 5393-5401.
33. Calderone, V.; Rapposelli, S.; Digiacomo, M.; Martelli, A.; Martinotti, E.; Balsamo, A. NO-sartans: new class of potential cardiovascular drugs, Raccolta degli atti, X Congresso Nazionale della Società' Italiana di ricerche cardiovascolari (S.I.R.C.), Roma; CLUEB: Bologna, 2003; p 139, 13.
34. Balsamo, A.; Calderone, V.; Digiacomo, M.; Martelli, A.; Martinotti, E.; Minutolo, F.; Rapposelli, S. NO-sartans: new class of potential cardiovascular drugs. Abstracts of Papers, 14th Camerino-Noordwijkerhout Symposium "Ongoing progress in the receptor chemistry", Società Chimica Italiana: Camerino, 2003, p 47, 117.
35. Earl, R. A.; Ezawa, M.; Fang, X.; Garvey, D. S.; Gaston, R. D.; Khanapure, S. P.; Letts, G. L.; Lin, C.-E.; Ranatunge, R. R.; Richardson, S. K.; Schroeder, J.D.; Stevenson, C. A.; Wey, S. J. WO Patent 2004004648, 2004.
36. Morsing, P.; Adler, G.; Brandt-Eliasson, U.; Karp, L.; Ohlson, K; Renberg, L.; Sjoquist, P. O.; Abrahamsson, T. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999, 33, 1406-1413.
37. Gilmer, J. F.; Moriarty, L. M.; Lally, M. N.; Clancy, J. M. Isosorbide-based aspirin prodrugs II. Hydrolysis kinetics of isosorbide diaspirinate. Eur. J. Pharm. Sci. 2002, 16 (4-5), 297-304.
38. Krege, J. H.; Hodgin, J. B.; Hagaman, J. R.; Smithies, O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 1995, 25, 1111-1115.
39. Rodrigo, E.; Maeso, R.; Munoz-Garcia, R.; Navarro-Cid, J.; Ruilope, L. M.; Cachofeiro, V.; Lacera, V. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J. Hypertens. 1997, 15 (6), 613-8.